Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_assertion type Assertion NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_head.
- NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_assertion wasGeneratedBy ECO_0000203 NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_provenance.
- NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_assertion wasDerivedFrom befree-2016 NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_provenance.
- NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_assertion SIO_000772 17713473 NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_provenance.
- NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_assertion evidence source_evidence_literature NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_provenance.
- NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_assertion description "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_provenance.